Where does Bioimagingtech rank among its competitors?

Bioimagingtech ranks 2201st amongst 1981 active competitors, of which 453 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Bioimagingtech?

Bioimagingtech's top competitors include Antheia, Transcenta and Akeso. Among them, Antheia secured the most recent funding round in January, 2026.

Bioimagingtech - 2026 Company Profile & Competitors

Company Details

Provider of research services for biological imaging and analysis technologies. Capabilities include high-content imaging, nanoparticle visualization, imaging flow cytometry, time-lapse microscopy, and various staining techniques. These services support investigations into cellular structure, proliferation, migration, pathogen infection mechanisms, and molecular interactions. The platform utilizes automated microscopy, multi-parameter algorithms, and quantitative software to analyze cellular, subcellular, and tissue samples. Support is provided for applications in drug discovery and development, including biomarker monitoring, pharmacokinetic studies, and drug efficacy or toxicity assessments. Additional offerings include reagents, embedding kits, and tissue microarrays for histology and pathology research. Scientists utilize these techniques to provide data for studies across microbiology, medicine, and biology.

Key Metrics

Stage

Unfunded

Ranked

2201^st among 2692 competitors

Similar Companies

Antheia & 2690 more

View Bioimagingtech's full profile

Bioimagingtech has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bioimagingtech include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Bioimagingtech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Fidelity Investments ... & 14 others	64/100
5th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
6th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
7th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
8th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
9th	enGene 1999, Saint laurent (Canada), Public	Developer of oral non-viral gene therapy platform	$54M	Hercules Capital, Lumira Ventures & 15 others	61/100
10th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	F-Prime Capital, Perceptive Advisors & 22 others	61/100
2201st	Bioimagingtech Unfunded	Provider of research services for biological imaging and analysis technologies	-	-	16/100